OTLK - CytoDyn's COVID-19 Trial And Other News: The Good Bad And Ugly Of Biopharma
CytoDyn advances enrolment in Phase 3 COVID-19 trial
CytoDyn Inc. (CYDY) announced that it has completed the enrollment for Phase 3 trial for COVID-19 patients with severe-to-critical symptoms. The trial is now eligible for an interim analysis following the 28-day phase. Leronlimab (PRO 140) is a CCR5 antagonist with the potential for multiple therapeutic indications.
The Phase 3 study is a two-arm, randomized, double-blind, placebo-controlled, adaptive design multicenter trial. It seeks to assess the safety and efficacy of leronlimab in patients suffering from severe-to-critical symptoms of respiratory illness caused by COVID-19. Nader Pourhassan,